




Tumor recurrence accompanied by resistance to 
treatment, i.e., the tumors respond to initial 
therapies but eventually re-emerge and become 
resistant to chemo/radiotherapy, remains a 
daunting clinical challenge. Recent studies sug-
gest that the drug-resistance of recurring tu-
mors may be due to a special small sub-
population of the malignancy named tumor-
initiating cells or cancer stem cells [1]. Cancer 
stem cells are thought to comprise only a frac-
tion of the tumor and maintain self-renewal, 
unlimited growth and differentiation capabili-
ties. These attributes make them responsible 
for tumor outgrowth, progression, drug-
resistance and metastasis [2].  
 
Existing knowledge about the hierarchical role 
of non-malignant stem cells in tissue mainte-
nance has driven much of the research into 
cancer stem cell biology. Adult stem cells are 
found in numerous tissues of the body and play 
a role in tissue development, replacement and 
repair [3]. Breast stem cells exhibit the two hall-
marks of stem cells, multipotency and self-
renewal. It has been shown that a single cell 
enriched with certain cell surface markers has 
the ability to grow a fully functional mammary 
gland in vivo [1, 4]. Similarly, a single cancer 
stem cell will establish a new tumor that dis-
plays the same heterogeneity of surface mark-
ers found in the tumor from whence it came. 
The cancer stem cell hypothesis arose from ob-
servations in haematopoietic malignancies but 
has since expanded to solid tumors. By using in 
vitro culture techniques and in vivo transplant 
models, investigators have established evi-
dence of cancer stem cells in colon, pancreas, 
prostate, brain and breast cancers [4-12]. The 
prevailing view is that cancer stem cells are a 
small sub-population of cells capable of self-
renewal and differentiation, although in some 
types of human cancers such as melanoma, 
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such tumorigenic cells may not be rare [13]. To 
be maximally effective, cancer therapy must be 
directed against both the largely quiescent pool 
of cancer stem cells as well as the more actively 
proliferating bulk tumor cells [14]. This may be 
possible if specific stem cell signals are inhib-
ited using molecularly targeted therapy, while at 
the same time attacking proliferating cells by 
conventional means [15, 16]. To achieve this 
goal, developments in microRNA regulation pre-
sent exciting prospects.  
  
MicroRNAs (miRNAs) are a conserved class of 
naturally occurring 20-22nt non-coding RNAs 
that regulate gene expression by binding to 
mRNA, leading to mRNA degradation or transla-
tional inhibition [17]. Our group recently re-
viewed miRNA biogenesis and outlined how the 
majority of miRNAs achieve specificity and acti-
vate the RNA interference pathway by 6-8 com-
plementary base pair interactions with the 3’ 
UTRs of their targets [18]. By this mechanism, 
they can regulate a variety of biological proc-
esses, including developmental timing, signal 
transduction, tissue differentiation and mainte-
nance, disease (for an interesting analysis of 
miRNA and disease processes see [19]), and 
carcinogenesis [17]. Indeed, multiple miRNAs 
have been reported as either oncogenes or tu-
mor suppressors. Emerging evidence demon-
strates that miRNAs play an essential role in 
stem cell self-renewal and differentiation by 
negatively regulating the expression of certain 
key genes in stem cells [17]. One study has 
shown that microRNA-21 knockdown disrupts 
glioma growth in vivo and displays synergistic 
cytotoxicity with neural precursor cell delivered 
S-TRAIL in human gliomas [20]. mi-R21 itself is 
an oncogene that is overexpressed in certain 
breast cancers and can affect tumorigenesis 
through modulating key players in apoptotic 
control including the proto-oncogene Bcl-2 [21-
23]. Other miRNAs, such as miR-15 and miR-
16, have been reported to downregulate Bcl-2. 
Their deletion in cancer allows for apoptosis 
inhibition when Bcl-2 is subsequently expressed 
at high levels [24, 25]. The obstacle to apop-
tosis due to overexpression of Bcl-2 results in 
an increased number of stem cells in vivo [26]. 
This suggests that apoptosis plays a role in 
regulating the microenvironments of stem cells 
[27].  
 
We recently demonstrated that miR-34 plays an 
important role in the p53 tumor suppressor net-
work.  Restoration of miR-34 reestablishes the 
tumor-suppressing signaling pathway in human 
gastric and pancreatic cancer cells lacking func-
tional p53 [28, 29]. As a result, miR-34 potently 
inhibits tumorsphere formation and growth in 
p53-mutant human gastric cancer cells, provid-
ing the first proof-of-concept that there is a po-
tential link between the tumor suppressor miR-
34 and cancer cell self-renewal [28]. In a differ-
ent model system, we recently reported that 
miR-34 inhibits CD44+/CD133+ pancreatic 
cancer stem cells self-renewal in vitro and tu-
mor-initiation in vivo [29]. The mechanism of 
miR-34-mediated suppression of gastric and 
pancreatic cancer stem cell self-renewal might 
be related to the direct modulation of down-
stream targets Bcl-2 and Notch, implying that 
miR-34 may be involved in cancer stem cell self-
renewal / differentiation decision-making [18, 
29]. Our data suggest that miR-34 may hold 
significant promise as a new class of molecular 
therapy for human gastric and pancreatic can-
cer, potentially by modulating cancer stem cells.  
 
Discussion and Future Directions 
 
miRNAs regulate a variety of biological proc-
esses, including developmental timing, signal 
transduction, tissue differentiation and mainte-
nance, disease, and carcinogenesis [17, 30]. 
Altered expression of specific miRNA genes con-
tributes to the initiation and progression of can-
cer [30]. Disruption of miRNA expression levels 
in tumor cells may result from distorted epige-
netic regulation of miRNA expression, abnor-
malities in miRNA processing genes or proteins, 
and the location of miRNAs at cancer-
associated genomic regions [31]. Clearly, 
miRNAs play a critical role in carcinogenesis as 
well as tumor progression [18, 32]. Certain ab-
normal miRNA expression levels cause cancer 
stem cell dysregulation, resulting in unlimited 
self-renewal and cancer progression [30, 33]. 
Therefore, microRNA expression is a vital key to 
cancer stem cell dysregulation [18]. In addition, 
a number of miRNAs have been identified within 
cancers to function as either oncogenes or tu-
mor suppressors [34, 35]. Silber et al. reported 
that miR-124 and miR-137 induce differentia-
tion of neural stem cells and glioblastoma stem 
cells and induce glioblastoma cell cycle arrest 
[36]. These results suggest that the targeted 
delivery of miR-124 and miR-137 to glioblas-
toma cells may be therapeutically efficacious for 
the treatment of this disease [36]. Another re-
microRNAs and cancer stem cells 
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cent study shows that miRNA Let-7 regulates 
self-renewal of breast cancer stem cells [33]. 
These miRNAs offer great promise for cancer 
therapy because they might have potential to 
regulate aberrant miRNA expression in cancer 
stem cells [18]. Thus miRNA therapy could be a 
powerful tool to correct the cancer stem cell 
dysregulation and its resulting excessive self-
renewal and cancer progression in patients.  
 
We have demonstrated the importance of miR-
34 and its relation to the p53 tumor suppressor 
network and cancer stem cells [18, 28, 29]. 
miR-34 targets Notch, cMET, HMGA2 and Bcl-2, 
genes involved in the self-renewal and survival 
of cancer stem cells, suggesting a potential role 
of miR-34 in cancer stem cells [18]. Restoration 
of miR-34 was able to re-establish the tumor 
suppressing signaling pathway in cancer cells 
lacking functional p53. More significantly, miR-
34 can inhibit cancer cell growth and tumor 
initiation via inhibiting the self-renewal of can-
cer stem cells. This indicates that miR-34 can 
function as a tumor suppressor gene in p53-
deficient cancer cells and that its loss-of-
function plays a role in the dysregulated self-
renewal in cancer stem cells [29]. More impor-
tantly, miR-34 restoration led to an 87% reduc-
tion of the CD44+/CD133+ tumor initiating cells 
(cancer stem cells), accompanied by significant 
inhibition of tumorsphere growth and tumor 
initiation in vivo [29]. 
 
If our hypothesis holds true, miRNAs like miR-34 
may play an important role in cancer stem cell 
self-renewal / differentiation processes. Deline-
ating the role of miR-34 in regulation of cell 
growth and tumor progression, and its relation-
ship with cancer stem cells, will help us better 
understand the p53 tumor suppressor signaling 
network, facilitate our research in carcinogene-
sis and cancer therapy, and build a solid foun-
dation for our exploration of novel strategies in 
diagnosis, treatment and prevention of cancer.  
Modulating cancer stem cell signaling pathways 
to improve chemotherapeutic response is an 
exciting new avenue for molecularly targeted 
therapy. The restoration of tumor suppressor 
miRNAs and/or inhibition of oncogenic miRNAs 
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